Challenges in UK Pharma and Investment Climate

This chapter delves into the hurdles faced by the UK pharmaceutical industry, focusing on issues like lack of competitiveness and inadequate government support for innovation. It examines the repercussions of underinvestment on patient access and health outcomes, while pushing for necessary policy changes and improved investment conditions. The discussion also reflects on the broader economic landscape post-COVID, analyzing the effects of fiscal tightening and rising interest rates on various sectors, including real estate.